Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19.
Identifieur interne : 000311 ( Main/Exploration ); précédent : 000310; suivant : 000312Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19.
Auteurs : Bérangère S. Joly [France] ; Virginie Siguret [France] ; Agnès Veyradier [France]Source :
- Intensive care medicine [ 1432-1238 ] ; 2020.
Descripteurs français
- KwdFr :
- Anticoagulants (usage thérapeutique), Betacoronavirus (physiologie), Humains (MeSH), Hémostase (physiologie), Infections à coronavirus (complications), Infections à coronavirus (immunologie), Infections à coronavirus (physiopathologie), Maladie grave (MeSH), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (immunologie), Pneumopathie virale (physiopathologie), Troubles de l'hémostase et de la coagulation (traitement médicamenteux), Troubles de l'hémostase et de la coagulation (étiologie).
- MESH :
- immunologie : Infections à coronavirus, Pneumopathie virale.
- physiologie : Betacoronavirus, Hémostase.
- physiopathologie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Troubles de l'hémostase et de la coagulation.
- usage thérapeutique : Anticoagulants, Infections à coronavirus, Pneumopathie virale.
- étiologie : Troubles de l'hémostase et de la coagulation.
- Humains, Maladie grave, Pandémies.
English descriptors
- KwdEn :
- Anticoagulants (therapeutic use), Betacoronavirus (physiology), Blood Coagulation Disorders (drug therapy), Blood Coagulation Disorders (etiology), Coronavirus Infections (complications), Coronavirus Infections (immunology), Coronavirus Infections (physiopathology), Critical Illness (MeSH), Cytokine Release Syndrome (etiology), Hemostasis (physiology), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (immunology), Pneumonia, Viral (physiopathology).
- MESH :
- chemical , therapeutic use : Anticoagulants.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Blood Coagulation Disorders.
- etiology : Blood Coagulation Disorders, Cytokine Release Syndrome.
- immunology : Coronavirus Infections, Pneumonia, Viral.
- physiology : Betacoronavirus, Hemostasis.
- physiopathology : Coronavirus Infections, Pneumonia, Viral.
- Critical Illness, Humans, Pandemics.
DOI: 10.1007/s00134-020-06088-1
PubMed: 32415314
PubMed Central: PMC7225398
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19.</title>
<author><name sortKey="Joly, Berangere S" sort="Joly, Berangere S" uniqKey="Joly B" first="Bérangère S" last="Joly">Bérangère S. Joly</name>
<affiliation wicri:level="3"><nlm:affiliation>EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Siguret, Virginie" sort="Siguret, Virginie" uniqKey="Siguret V" first="Virginie" last="Siguret">Virginie Siguret</name>
<affiliation wicri:level="3"><nlm:affiliation>UMR-S1140 Inserm, Innovative Therapeutics in Haemostasis, Université de Paris, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>UMR-S1140 Inserm, Innovative Therapeutics in Haemostasis, Université de Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Veyradier, Agnes" sort="Veyradier, Agnes" uniqKey="Veyradier A" first="Agnès" last="Veyradier">Agnès Veyradier</name>
<affiliation wicri:level="3"><nlm:affiliation>EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris, France. agnes.veyradier@aphp.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32415314</idno>
<idno type="pmid">32415314</idno>
<idno type="doi">10.1007/s00134-020-06088-1</idno>
<idno type="pmc">PMC7225398</idno>
<idno type="wicri:Area/Main/Corpus">001273</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001273</idno>
<idno type="wicri:Area/Main/Curation">001273</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001273</idno>
<idno type="wicri:Area/Main/Exploration">001273</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19.</title>
<author><name sortKey="Joly, Berangere S" sort="Joly, Berangere S" uniqKey="Joly B" first="Bérangère S" last="Joly">Bérangère S. Joly</name>
<affiliation wicri:level="3"><nlm:affiliation>EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Siguret, Virginie" sort="Siguret, Virginie" uniqKey="Siguret V" first="Virginie" last="Siguret">Virginie Siguret</name>
<affiliation wicri:level="3"><nlm:affiliation>UMR-S1140 Inserm, Innovative Therapeutics in Haemostasis, Université de Paris, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>UMR-S1140 Inserm, Innovative Therapeutics in Haemostasis, Université de Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Veyradier, Agnes" sort="Veyradier, Agnes" uniqKey="Veyradier A" first="Agnès" last="Veyradier">Agnès Veyradier</name>
<affiliation wicri:level="3"><nlm:affiliation>EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris, France. agnes.veyradier@aphp.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Intensive care medicine</title>
<idno type="eISSN">1432-1238</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticoagulants (therapeutic use)</term>
<term>Betacoronavirus (physiology)</term>
<term>Blood Coagulation Disorders (drug therapy)</term>
<term>Blood Coagulation Disorders (etiology)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (immunology)</term>
<term>Coronavirus Infections (physiopathology)</term>
<term>Critical Illness (MeSH)</term>
<term>Cytokine Release Syndrome (etiology)</term>
<term>Hemostasis (physiology)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (physiopathology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticoagulants (usage thérapeutique)</term>
<term>Betacoronavirus (physiologie)</term>
<term>Humains (MeSH)</term>
<term>Hémostase (physiologie)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (immunologie)</term>
<term>Infections à coronavirus (physiopathologie)</term>
<term>Maladie grave (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (immunologie)</term>
<term>Pneumopathie virale (physiopathologie)</term>
<term>Troubles de l'hémostase et de la coagulation (traitement médicamenteux)</term>
<term>Troubles de l'hémostase et de la coagulation (étiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticoagulants</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blood Coagulation Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Blood Coagulation Disorders</term>
<term>Cytokine Release Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term>
<term>Hémostase</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term>
<term>Hemostasis</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Troubles de l'hémostase et de la coagulation</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticoagulants</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Troubles de l'hémostase et de la coagulation</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Critical Illness</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Maladie grave</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32415314</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1238</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>46</Volume>
<Issue>8</Issue>
<PubDate><Year>2020</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Intensive care medicine</Title>
<ISOAbbreviation>Intensive Care Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>1603-1606</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00134-020-06088-1</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joly</LastName>
<ForeName>Bérangère S</ForeName>
<Initials>BS</Initials>
<AffiliationInfo><Affiliation>EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Siguret</LastName>
<ForeName>Virginie</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>UMR-S1140 Inserm, Innovative Therapeutics in Haemostasis, Université de Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Veyradier</LastName>
<ForeName>Agnès</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-9551-3076</Identifier>
<AffiliationInfo><Affiliation>EA-3518, Clinical Research in Hematology, Immunology and Transplantation, Institut de Recherche Saint-Louis, Hôpital Saint Louis, Université de Paris, Paris, France. agnes.veyradier@aphp.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Intensive Care Med</MedlineTA>
<NlmUniqueID>7704851</NlmUniqueID>
<ISSNLinking>0342-4642</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001778" MajorTopicYN="N">Blood Coagulation Disorders</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006487" MajorTopicYN="N">Hemostasis</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32415314</ArticleId>
<ArticleId IdType="doi">10.1007/s00134-020-06088-1</ArticleId>
<ArticleId IdType="pii">10.1007/s00134-020-06088-1</ArticleId>
<ArticleId IdType="pmc">PMC7225398</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Br J Haematol. 2020 Jun;189(6):1044-1049</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330308</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2020 Jul 7;142(1):68-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32293910</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 May;18(5):1023-1026</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32338827</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thromb Res. 2020 Jul;191:9-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32353746</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Resusc. 2020 Apr 15;22(2):95-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32294809</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thromb Res. 2020 Jul;191:145-147</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32291094</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32311448</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 May;18(5):1094-1099</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 Jul;18(7):1738-1742</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32302438</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 2020 May;214:108393</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32222466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 2;395(10234):1417-1418</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32325026</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2020 Jun;46(6):1117-1120</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32253448</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 Apr;18(4):844-847</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32073213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619887437</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31775524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2020 Jun;46(6):1089-1098</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32367170</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Joly, Berangere S" sort="Joly, Berangere S" uniqKey="Joly B" first="Bérangère S" last="Joly">Bérangère S. Joly</name>
</region>
<name sortKey="Siguret, Virginie" sort="Siguret, Virginie" uniqKey="Siguret V" first="Virginie" last="Siguret">Virginie Siguret</name>
<name sortKey="Veyradier, Agnes" sort="Veyradier, Agnes" uniqKey="Veyradier A" first="Agnès" last="Veyradier">Agnès Veyradier</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000311 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000311 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidFranceV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32415314 |texte= Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32415314" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidFranceV1
This area was generated with Dilib version V0.6.37. |